Premium
Thalidomide: An option for the pediatric patient with actinic prurigo
Author(s) -
WattsSantos Anabella,
MartinezRico Jessica Carolina,
GomezFlores Minerva,
OcampoCandiani Jorge,
AlbaRojas Erika
Publication year - 2019
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14086
Subject(s) - medicine , thalidomide , photodermatosis , dermatology , prurigo , girl , pediatrics , immunology , xeroderma pigmentosum , dna , psychology , developmental psychology , genetics , biology , multiple myeloma , dna damage
Actinic prurigo (AP) is an immune‐mediated photodermatosis that usually starts in childhood and is predominant among American indigenous and mestizo communities. In adults with AP, thalidomide is the treatment of choice; however, there is little information on its use in pediatric patients. We report the case of a 10‐year‐old girl with AP treated successfully with thalidomide.